RVX Share Price

Open 2.02 Change Price %
High 2.02 1 Day -0.01 -0.50
Low 1.94 1 Week -0.14 -6.51
Close 2.01 1 Month -0.17 -7.80
Volume 20450 1 Year 0.67 50.00
52 Week High 2.47
52 Week Low 1.10
RVX Important Levels
Resistance 2 2.08
Resistance 1 2.05
Pivot 1.99
Support 1 1.97
Support 2 1.94
TSE Canada Most Active Stocks
TD 66.80 0.18%
TD 66.80 0.18%
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
ABX 22.89 -10.97%
ABX 22.89 -10.97%
ABX 22.89 -10.97%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
DNT 0.10 25.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
GLG 0.34 9.68%
More..
TSE Canada Top Losers Stocks
TPL 0.02 -33.33%
TPL 0.02 -33.33%
LRT-UN 0.03 -25.00%
GBV 0.46 -24.59%
YRB-A 0.08 -11.11%
ABX 22.89 -10.97%
ABX 22.89 -10.97%
ABX 22.89 -10.97%
CTU-A 0.19 -9.52%
E 0.31 -8.82%
More..

Resverlogix Corp (TSE: RVX)

RVX Technical Analysis 1.5
As on 25th Apr 2017 RVX Share Price closed @ 2.01 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.70 & Sell for SHORT-TERM with Stoploss of 2.10 we also expect STOCK to react on Following IMPORTANT LEVELS.
RVX Target for April
1st Target up-side 2.39
2nd Target up-side 2.57
3rd Target up-side 2.74
1st Target down-side 1.89
2nd Target down-side 1.71
3rd Target down-side 1.54
RVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.resverlogix.com
RVX Address
RVX
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada
Phone: 403-254-9252
Fax: 403-256-8495
Interactive Technical Analysis Chart Resverlogix Corp ( RVX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Resverlogix Corp
RVX Business Profile
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.